PTPI vs PRGO vs HIMS vs MNKD vs LLY

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -12. 2% for Petros Pharmaceuticals, Inc. (PTPI). Eli Lilly and Company (LLY) offers the better valuation at 41. 3x trailing P/E (26. 3x forward), making it the more compelling value choice. Analysts rate MannKind Corporation (MNKD) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Eli Lilly and Company (LLY) is the cheapest at 41.

3x versus MannKind Corporation at 176. 0x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +399.

3%, compared to -100. 0% for Petros Pharmaceuticals, Inc. (PTPI). Over 10 years, the gap is even starker: LLY returned +1203% versus PTPI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Eli Lilly and Company (LLY) is the lower-risk stock at 0.

65β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately 280% more volatile than LLY relative to the S&P 500. On balance sheet safety, Perrigo Company plc (PRGO) carries a lower debt/equity ratio of 135% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -12. 2% for Petros Pharmaceuticals, Inc. (PTPI). On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96. 0% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus -280. 1% for Petros Pharmaceuticals, Inc. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -345. 8% for PTPI. At the gross margin level — before operating expenses — LLY leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

5x forward P/E versus 58. 3x for Hims & Hers Health, Inc. — 52. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 209. 1% to $36. 20.

In this comparison, PTPI (100.

0% yield), PRGO (9. 8% yield), LLY (0. 6% yield) pay a dividend. HIMS, MNKD do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

65), 0. 6% yield, +1203% 10Y return). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 48 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LLY: +1203%, HIMS: +188. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PTPI is a small-cap income-oriented stock; PRGO is a small-cap income-oriented stock; HIMS is a small-cap high-growth stock; MNKD is a small-cap high-growth stock; LLY is a large-cap high-growth stock. PTPI, PRGO, LLY pay a dividend while HIMS, MNKD do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.